Blockchain Registration Transaction Record

AXIM Submits 510(k) for Rapid Dry Eye Test, Eyes CLIA Waiver

AXIM Biotechnologies submits 510(k) to FDA for a rapid, point-of-care dry eye test measuring lactoferrin. Plans CLIA waiver to expand access in eye care offices.

This news matters because dry eye disease is a widespread and often frustrating condition for both patients and clinicians. Current diagnostic methods are frequently subjective, leading to misdiagnosis or delayed treatment. An objective, rapid test for lactoferrin could enable earlier and more accurate identification of aqueous deficient dry eye, allowing for targeted therapies and better monitoring. By seeking CLIA waiver, AXIM aims to make this test accessible in routine eye care settings, potentially revolutionizing how dry eye is managed. For the millions of Americans suffering from dry eye, this could mean faster relief and more personalized care. Moreover, it signals a broader trend toward point-of-care diagnostics in ophthalmology, which could improve efficiency and patient outcomes.